OncoMatch/Clinical Trials/NCT05636787
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Is NCT05636787 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Treosulfan and Melphalan for multiple myeloma.
Treatment: Treosulfan · Melphalan — Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: induction chemotherapy — first-line
myeloma patients after standard first-line induction treatment
Cannot have received: anti-cancer investigational agent
Use of any anti-cancer investigational agents within 14 days prior to the expected start of trial treatment
Lab requirements
Kidney function
creatinine clearance ≥35 ml/min
Cardiac function
lvef ≥40% within three months prior to start of study hdct
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05636787 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-cancer investigational agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages